"10.1371_journal.pmed.1001013","plos medicine","2011-03-22T00:00:00Z","Jane E Salmon; Cara Heuser; Michael Triebwasser; M Kathryn Liszewski; David Kavanagh; Lubka Roumenina; D Ware Branch; Tim Goodship; Veronique Fremeaux-Bacchi; John P Atkinson","Autoimmunity and Inflammation Program, Hospital for Special Surgery, Cornell Weill Medical College, New York, New York, United States of America; Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, United States of America; Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom; Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges-Pompidou, Service dImmunologie Biologique, Paris, France","Conceived and designed the experiments: JES JAP MT VFB TG. Performed the experiments: VFB LR DK MKL TG. Analyzed the data: JES JAP TG MT VFB. Contributed reagents/materials/analysis tools: CH DWB DK MT MKL VBF TG JAP JES. Wrote the paper: JES MT MKL DK VFB JPA. ICMJE criteria for authorship: JES CH MT MKL DK LR DWB TG VFB JPA. Agree with result and conclusions: JES CH MT MKL DK LR DWB VFB TG JPA. Enrolled patients: CH JES DWB TG VFB. Wrote the first draft: JES CH MT MKL DK VFB JPA.","JES holds stock in Taligen Therapeutics. JPA is on the Scientific Advisory Board and holds stock in Taligen Therapeutics. TG has acted as a Scientific Advisor for Taligen Therapeutics. All other authors have no conflict of interest.","2011","03","Jane E Salmon","JES",10,TRUE,5,5,5,6,TRUE,TRUE,FALSE,0,NA,FALSE
